The Analyst Landscape: 7 Takes On Avidity Biosciences
Portfolio Pulse from Benzinga Insights
In the past three months, 7 analysts have provided ratings for Avidity Biosciences (NASDAQ:RNA), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 20.87% to $47.14. Analysts have raised their price targets, reflecting positive market sentiment and recent company performance.
August 12, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avidity Biosciences (NASDAQ:RNA) has received predominantly bullish ratings from analysts over the past three months. The average 12-month price target has increased by 20.87% to $47.14, indicating positive sentiment and expectations for the company's future performance.
The increase in the average price target and the predominantly bullish ratings from analysts suggest a positive short-term impact on Avidity Biosciences' stock price. The raised price targets reflect improved market sentiment and expectations for the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100